Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Fraser Hornby"'
Autor:
Markel Martínez-Carranza, Jana Škerlová, Pyung-Gang Lee, Jie Zhang, Ajda Krč, Abhishek Sirohiwal, Dave Burgin, Mark Elliott, Jules Philippe, Sarah Donald, Fraser Hornby, Linda Henriksson, Geoffrey Masuyer, Ville R. I. Kaila, Matthew Beard, Min Dong, Pål Stenmark
Publikováno v:
Communications Chemistry, Vol 7, Iss 1, Pp 1-15 (2024)
Abstract Botulinum neurotoxins (BoNTs) are the most potent toxins known and are used to treat an increasing number of medical disorders. All BoNTs are naturally co-expressed with a protective partner protein (NTNH) with which they form a 300 kDa comp
Externí odkaz:
https://doaj.org/article/76a86350a53746c793c2709f2f9104e9
Autor:
Hodan Ibrahim, Kevin Retailleau, Fraser Hornby, Jacquie Maignel, Matthew Beard, Donna Marie Daly
Publikováno v:
Toxins, Vol 16, Iss 1, p 30 (2024)
Botulinum neurotoxin A (BoNT/A) is a potent neurotoxin that silences cholinergic neurotransmission through the cleavage of the synaptic protein SNAP-25. Previous studies have shown that, in addition to its paralytic effects, BoNT/A can inhibit sensor
Externí odkaz:
https://doaj.org/article/539d303bc0134f4480d60c956db88901
Publikováno v:
Toxins, Vol 14, Iss 1, p 53 (2022)
Botulinum neurotoxin (BoNT/A) is an FDA and NICE approved second-line treatment for overactive bladder (OAB) in patients either not responsive or intolerant to anti-cholinergic drugs. BoNT/A acts to weaken muscle contraction by blocking release of th
Externí odkaz:
https://doaj.org/article/054d7dcc6d9f4702ac443422a2cb1106
Autor:
Jacquie Maignel, Vincent Martin, Rana Assaly, Mathieu L. Vogt, Kevin Retailleau, Fraser Hornby, Alexandra Laugerotte, Stéphane Lezmi, Pierre Denys, Johannes Krupp, Charles Joussain
Publikováno v:
Toxins, Vol 14, Iss 2, p 77 (2022)
Management of neurogenic detrusor overactivity (NDO) remains a clinical priority to improve patients’ quality of life and prevent dramatic urological complications. Intradetrusor injection of onabotulinumtoxinA (BoNT/A1, botulinum neurotoxin A1) is
Externí odkaz:
https://doaj.org/article/1e2b790ec64c403b8d55ae70988968cb
Autor:
David Burgin, Cindy Périer, Gavin Hackett, Mark Elliott, Daniel Kwan, Fraser Hornby, Imran Mir, Jacquie Maignel, Sai Man Liu, Matthew Beard
Publikováno v:
Toxins, Vol 13, Iss 12, p 834 (2021)
Botulinum neurotoxins (BoNTs) are notorious toxins and powerful agents and can be lethal, causing botulism, but they are also widely used as therapeutics, particularly to treat neuromuscular disorders. As of today, the commercial BoNT treatments avai
Externí odkaz:
https://doaj.org/article/c99d92ffcf0a47c4b7272dba7e441b2e
Autor:
Mark Elliott, Jacquie Maignel, Sai Man Liu, Christine Favre-Guilmard, Imran Mir, Paul Farrow, Fraser Hornby, Sandra Marlin, Shilpa Palan, Matthew Beard, Johannes Krupp
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0185628 (2017)
Botulinum neurotoxins (BoNTs) are used extensively as therapeutic agents. Serotypes A and B are available as marketed products. Higher doses of BoNT/B are required to reach an efficacy similar to that of products containing BoNT/A. Advances in our un
Externí odkaz:
https://doaj.org/article/624c145a76ff4bdfbc84f35181129cd7
Autor:
Markel Martínez-Carranza, Jana Škerlová, Pyung-Gang Lee, Jie Zhang, Dave Burgin, Mark Elliott, Jules Philippe, Sarah Donald, Fraser Hornby, Linda Henriksson, Geoffrey Masuyer, Matthew Beard, Min Dong, Pål Stenmark
Publikováno v:
bioRxiv
Botulinum neurotoxins (BoNTs) are the most potent toxins known and are used to treat an increasing number of medical disorders. All BoNTs are naturally co-expressed with a protective partner protein (NTNH) with which they form a 300 kDa complex, to r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8223117d2d82441ba876f3ddb17493e
https://europepmc.org/articles/PMC9882044/
https://europepmc.org/articles/PMC9882044/
Autor:
Jacquie Maignel, Vincent Martin, Rana Assaly, Mathieu L. Vogt, Kevin Retailleau, Fraser Hornby, Alexandra Laugerotte, Stéphane Lezmi, Pierre Denys, Johannes Krupp, Charles Joussain
Publikováno v:
Toxins; Volume 14; Issue 2; Pages: 77
Management of neurogenic detrusor overactivity (NDO) remains a clinical priority to improve patients’ quality of life and prevent dramatic urological complications. Intradetrusor injection of onabotulinumtoxinA (BoNT/A1, botulinum neurotoxin A1) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc9aeb221c92ec06659503afb514e03
https://pubmed.ncbi.nlm.nih.gov/35202105
https://pubmed.ncbi.nlm.nih.gov/35202105
Autor:
Sandra Marlin, Bryony Gray, Fraser Hornby, Mark Elliott, Elena Fonfria, Johannes Krupp, Cindy Perier, Sylvie Cornet, Christine Favre-Guilmard, Mikhail Kalinichev, Sarah Donald, Agnieszka Lewandowska
Publikováno v:
Pharmacology Research & Perspectives
Botulinum neurotoxin (BoNT) is a major therapeutic agent. Of seven native BoNT serotypes (A to G), only A and B are currently used in the clinic. Here we compared the potency of commercially available purified native serotypes A1 to F1 across in vitr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::307cd6a8d2e78ed22b8ad59f002d7baa
https://pubmed.ncbi.nlm.nih.gov/30519475
https://pubmed.ncbi.nlm.nih.gov/30519475
Autor:
Fraser Hornby, Gavin Hackett, Imran Mir, Kevin Moore, David Burgin, Mark Elliott, Bryony Gray, Matthew Beard
Publikováno v:
Toxins
Toxins; Volume 10; Issue 5; Pages: 195
Toxins; Volume 10; Issue 5; Pages: 195
We have purified and characterized recombinant botulinum neurotoxin serotype FA (BoNT/FA). This protein has also been named as a new serotype (serotype H), but the classification has been controversial. A lack of well-characterized, highly pure mater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24835f739933c45c02e3d8447a473b2
http://europepmc.org/articles/PMC5983251
http://europepmc.org/articles/PMC5983251